BioLineRx (BLRX) vs Can-Fite Biopharma (CANF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BioLineRx (BLRX) has outperformed Can-Fite Biopharma (CANF) over the past year, losing 70.3% versus a loss of 75.3%. Over five years, BLRX leads with a -99.1% price change compared with -99.4% for CANF. BioLineRx is the larger company by market cap ($4.8 million vs $4.4 million), about 1.1 times the size, while Can-Fite Biopharma is growing revenue faster (-39.9% vs -95.9%).
BioLineRx converts more of its revenue into profit, with a net margin of -171.7% versus -2426.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLRX | CANF |
|---|---|---|
| Share price | $0.9639 | $1.44 |
| Market cap | $4.80M | $4.35M |
| 1-day change | -8.20% | -2.34% |
| YTD return | -65.20% | -64.13% |
| 1-year return | -70.34% | -75.26% |
| 5-year return | -99.07% | -99.42% |
| EPS (TTM) | $0.00 | $-13.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.18M | $405.00K |
| Revenue growth (YoY) | -95.92% | -39.91% |
| Net income (latest FY) | $-2.03M | $-9.83M |
| Gross margin | 80.51% | — |
| Operating margin | -871.78% | -2456.79% |
| Net margin | -171.69% | -2426.67% |
| 52-week high | $3.95 | $10.40 |
| 52-week low | $0.78 | $1.42 |
| Distance from 52-week high | -75.60% | -86.20% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +2182.39% | +457.49% |
| Average volume | 23.43K | 375.00K |
| Shares outstanding | 4.98M | 3.03M |
| Employees | 20 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BioLineRx is more profitable, keeping -171.7 cents of every revenue dollar as net income versus -2426.7 cents for Can-Fite Biopharma.
- Can-Fite Biopharma grew revenue faster in its latest fiscal year (-39.91% vs -95.92%).
About BioLineRx
BLRX stock →BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About Can-Fite Biopharma
CANF stock →Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
BLRX vs CANF FAQ
Which is bigger, BioLineRx or Can-Fite Biopharma?
BioLineRx (BLRX) is larger, with a market capitalization of $4.80M compared with $4.35M for Can-Fite Biopharma (CANF).
Which stock has performed better over the past year, BLRX or CANF?
BLRX returned -70.34% over the past 12 months, compared with -75.26% for CANF (price return, excluding dividends). Past performance does not predict future results.
Are BioLineRx and Can-Fite Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.